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No way to treat a tumor
O
n page 93, Yuneva et al. provide bittersweet news for efforts 
to turn cancer cells’ big appetite against them. Contrary to previous 
work, the study shows that a sugar shortage snuffs out normal 
cells as well as cancer cells. But the results bolster another nutritional 
target: the amino acid glutamine.
The idea that cancer cells hunger for glucose is more than 50 years 
old. In the 1990s, researchers showed that glucose depletion kills rodent 
cells that carry an overactive form of the cancer-promoting gene MYC. 
Nontransformed cells survived.
Tumors also need plenty of glutamine, and two drugs that disrupt 
metabolism of the amino acid reached clinical trials but have since proved 
toxic. Some scientists question whether scarcity of either nutrient is lethal to 
human tumors: cancer cells synthesize their own glutamine, and some tumors 
switch to alternative food sources if glucose runs out. Yuneva et al. wanted to 
nail down whether the nutrients are essential for cells with overactive MYC.
To their surprise, the researchers found that, unlike rodent cells, human 
cells were killed by glucose deprivation whether or not extra MYC was 
present. By contrast, shutting off the glutamine supply had a stronger effect 
on MYC-overproducing cells. The results suggest that glutamine deprivation 
as a cancer treatment—which researchers have abandoned—deserves a 
second look. The fi  ndings don’t show that glucose deprivation is a bust, the 
authors caution. Instead, they say, scientists need to carefully compare the 
intricacies of metabolism in normal and cancer cells before they can predict 
whether such treatments will work. 
Mitochondria on the 
MARCH
B
reaking up isn’t hard to do for mito-
chondria, which are continually sepa-
rating and merging. On page 71, 
  Karbowski et al. pinpoint a protein that prods 
the organelles to go their own way.
Cells carefully control mitochondrial fusion 
and ﬁ   ssion, and an imbalance between the 
processes can be disastrous. For example, a 
faulty fusion-promoting protein triggers domi-
nant optic atrophy, the leading cause of inher-
ited blindness. Researchers know more about 
the regulation of fusion and ﬁ   ssion in yeast 
than in mammals. But they do know that one of 
the mammalian proteins essential for mitochon-
drial breakup is Drp1.
Karbowski et al. pinpointed another, 
called MARCH5, which colocalizes with Drp1. 
Although two studies published last year 
suggested that MARCH5 promoted mitochon-
drial fusion, the scientists now ﬁ  nd the oppo-
site. When they altered cells to produce a 
defective version of the protein, mitochondria 
stuck together to form extra-long networks 
instead of breaking apart. The researchers 
also observed this abnormal elongation when 
they added RNAi against MARCH5.
The protein normally spreads out around 
the mitochondrial membrane, but the mutant 
MARCH5 clumped. These clusters trapped 
Drp1. These ﬁ   ndings suggest that MARCH5 
spurs mitochondrial splitting by helping to di-
rect Drp1 to the future separation site. MARCH5 
is a ubiquitin ligase that works by attaching a 
ubiquitin molecule to its target. The researchers’ 
next move is to track down that target. 
p53 hits the brakes
C
rawling cells shift into high gear after 
they lose the tumor suppressor protein 
p53, as Gadea et al. report on page 
23. The work reveals that the same ﬂ  aw that 
allows cancer cells to divide uncontrollably 
also increases their mobility.
Most cancer cells sport faulty versions of 
p53, which normally halts the cell cycle or 
triggers apoptosis in response to DNA dam-
age. The researchers and other groups had 
previously shown that deleting p53 gets cells 
moving in two-dimensional cultures. Gadea 
et al. tested for the same effect in more realis-
tic, three-dimensional cultures.
The researchers found that crawling mouse 
embryonic ﬁ  broblasts came in two varieties. If 
they carried working p53, the cells were elon-
gated and sluggish. But if p53 was absent, they 
were rounder and slithered six times faster. This 
speedier movement required RhoA GTPase and 
its downstream enforcer, ROCK.
Inactivating p53 in melanoma cells that normally carry a functional 
version of the protein increases their invasiveness, conﬁ  rming that p53 loss 
can accelerate the dispersion of cancer cells. The results suggest that 
cancer treatments that restore p53 activity bring an added beneﬁ  t by 
reining in the rogue cells. 
Mitochondria (red) are stickier in cells that make 
faulty MARCH5 (green).
A p53-expressing ﬁ  bro-
blast (top) is outrun by a 
fast crawler lacking p53 
(bottom).